A 14.5% drop in prescription drug TV spending sounds like an industry retreat. But what if part of the decline came from a shorter baseball postseason? It’s a useful example of pharma media economics: advertising spending can change even when a brand’s strategy stays the same. Budgets respond not only to strategy, but also to which premium ad slots exist and what they cost. October 2026 brought a steep linear TV decline and a modest streaming gain. However, those figures alone cannot tell us whether brands changed their plans or faced a different sports calendar.
Table of Contents
- What October’s TV Spending Numbers Show
- How Baseball Affects Premium Advertising Inventory
- Why Streaming Gains Do Not Settle the Question
- What Pharma Media Planners Should Measure
- Conclusion
- FAQ
What October’s TV Spending Numbers Show
According to EMARKETER’s analysis of iSpot data, prescription drug TV spending reached $706 million in October 2026, down from $826 million a year earlier. That’s $120 million less.
The channel split is also striking. Linear TV spending fell 22%, while streaming TV spending rose 4.4%. Meanwhile, the usual seasonal surge was weaker. Linear prescription drug advertising grew just 8.5% from September to October, compared with 23% during those months in 2025.
Together, those numbers describe an unusual buying month. However, spending estimates show where advertisers placed dollars, not every reason behind their choices. They also do not reveal drugmakers’ entire promotional budgets.
For example, a smaller bill could reflect fewer advertising opportunities, different rates, or a deliberate budget cut. Likewise, an expensive placement can lift spending without delivering a matching rise in reach.
Consequently, marketers need to distinguish between rising advertising costs and changes in how many viewers their campaigns actually reach. Otherwise, they risk treating normal changes in media supply as evidence of a major shift in pharmaceutical advertising strategy.
How Baseball Affects Premium Advertising Inventory
Live sports accounted for 31% of national linear prescription drug TV spending in October, according to iSpot. Yet postseason schedules vary considerably from year to year.
Major League Baseball played 32 postseason games in October 2026, compared with 42 in October 2025. Advertisers therefore had 10 fewer October playoff games in which to appear. When a series ends early, expected commercial breaks disappear. Advertisers cannot buy a Game 7 that never happens.
Still, game counts do not establish how many pharma advertising dollars were lost. World Series spots carry different prices from earlier playoff placements. Audience size, matchups, broadcast networks, commercial lengths, and negotiated rates all matter.
Moreover, advertisers might move their commitments to other broadcasts or receive replacement spots. A shorter postseason does not automatically mean that every dollar allocated to baseball disappears from the advertising market.
Consider two pharmaceutical brands with identical sports advertising plans. One might pay more because its commercials appear during expensive games with large audiences. Another might spend less because a playoff series ends sooner. Neither outcome necessarily proves a change in marketing priorities.
As a result, fewer available advertising slots can make it look like pharmaceutical companies are cutting their TV budgets, even when their overall strategies haven’t changed.
Therefore, blaming the entire October spending decline on baseball would be just as misleading as ignoring baseball’s influence altogether. The real challenge is determining how much of the decline reflects media availability rather than intentional reductions in advertising investment.
Why Streaming Gains Do Not Settle the Question
Streaming’s 4.4% increase suggests that advertisers continue to value digital video. Connected TV can help pharmaceutical brands reach relevant audiences and coordinate campaigns with search, patient education, and other marketing channels.
Pharma Marketing Network’s analysis of Ardelyx’s streaming-first Ibsrela campaign shows how connected TV can support a broader pharmaceutical marketing strategy. In that approach, a television commercial starts a conversation rather than carrying the entire burden of patient education.
However, streaming growth does not prove that lost linear TV dollars moved directly into connected TV. Those percentage changes come from different spending bases and cannot simply be subtracted from one another.
Some pharmaceutical brands may have shifted their media investments toward streaming, while others reduced television activity overall. Meanwhile, certain advertisers may have increased spending across multiple channels.
Brand decisions can also move against broader industry trends. For example, the Network’s analysis of Bimzelx’s TV advertising surge shows why a pharmaceutical company might invest heavily in traditional television to build brand awareness.
That’s why industry-wide spending figures don’t always tell the full story of how individual pharmaceutical brands invest in advertising.
A category-wide decline can occur alongside major investments by specific brands. Likewise, streaming growth can reflect meaningful strategic changes without explaining the entire decrease in linear TV spending.
What Pharma Media Planners Should Measure
The first step is comparing advertising spending with the inventory available to buy. Agencies should review planned versus aired placements, especially around playoff games that never occurred. That helps separate scheduling effects from intentional budget reductions.
Next, marketing teams should examine cost per thousand impressions, audience reach, frequency, and unique viewer delivery. A lower advertising spend may still produce strong reach, while a higher bill may simply reflect more expensive commercial placements.
Then, planners should compare similar sporting events across years and evaluate the full postseason rather than focusing exclusively on October. After all, playoff schedules can shift between months, making year-over-year comparisons less straightforward.
Changes in commercial length, replacement advertising spots, and negotiated media rates also deserve attention. Without those details, spending totals can create an incomplete picture of advertising effectiveness.
Furthermore, marketers should look at how television contributes to a broader campaign. A commercial might introduce a drug brand, while digital advertising, paid search, and educational content help interested consumers find additional information.
Finally, pharmaceutical marketers need to look beyond advertising exposure and measure whether their campaigns are achieving meaningful business results.
Brand awareness, relevant searches, qualified website visits, and responsibly measured patient engagement can provide useful context. However, those measurements must also respect privacy requirements and pharmaceutical advertising regulations.
The same principles apply to healthcare digital marketing campaigns supported by providers such as eHealthcare Solutions, where audience relevance and advertising performance are important considerations.
No single analysis can explain every advertising dollar. Instead, the goal is to understand whether spending changed because of strategy, higher media prices, or fewer available commercial placements. That understanding can help pharmaceutical marketers make better decisions during future media negotiations.
Conclusion
October’s 14.5% decline in prescription drug television spending is significant, but its meaning is not simple. Fewer baseball playoff games likely reduced premium advertising opportunities, while streaming continued to attract additional investment.
Yet the available figures do not establish exactly how much baseball contributed to the $120 million spending decline. Before declaring a permanent change in pharmaceutical advertising strategy, marketers should examine inventory availability, advertising costs, and audience delivery together.
Ultimately, understanding why advertising dollars move matters just as much as tracking where they go.
FAQ
Why did pharma TV spending fall in October 2026?
Prescription drug TV spending fell amid weaker linear television investment and fewer MLB postseason games. However, the available data cannot isolate the exact contribution of each factor.
Did baseball cause the entire 14.5% spending decline?
That has not been established. October had 10 fewer MLB postseason games than the previous year, but advertising rates, inventory availability, and individual brand decisions also influence spending.
Is pharmaceutical advertising moving from linear TV to streaming?
Streaming spending increased while linear television investment declined. However, one month’s data cannot establish whether advertisers directly transferred their budgets between channels.
How should pharma brands evaluate live sports advertising?
Brands should compare planned and aired placements, advertising prices, audience reach, and campaign outcomes. They should also account for postseason games that were scheduled but never played.
Why is advertising inventory important to pharmaceutical media planning?
Premium advertising opportunities are limited, especially during major sporting events. Changes in their availability and cost can affect campaign spending even when pharmaceutical brands maintain consistent marketing strategies.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.
